CytRx Corporation (NASDAQ: CYTR) announced that tamibarotene, currently under evaluation in a U.S. registration trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE